Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Journal of Interdisciplinary Medicine
Volume 6 (2021): Issue 3 (September 2021)
Open Access
The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)
Nimród László
Nimród László
,
Hédy Katalin Sárközy
Hédy Katalin Sárközy
,
Cristina Alexandra Man
Cristina Alexandra Man
,
Edith Simona Ianoși
Edith Simona Ianoși
,
Botond Mátyás
Botond Mátyás
,
Bianca Emilia Ciurba
Bianca Emilia Ciurba
,
Corina Mărginean
Corina Mărginean
and
Gabriela Jimborean
Gabriela Jimborean
| Oct 14, 2021
Journal of Interdisciplinary Medicine
Volume 6 (2021): Issue 3 (September 2021)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Oct 14, 2021
Page range:
157 - 161
Received:
Sep 04, 2021
Accepted:
Sep 11, 2021
DOI:
https://doi.org/10.2478/jim-2021-0030
Keywords
monoclonal antibody therapy
,
severe eosinophilic asthma
,
clinical parameters
,
eosinophils
© 2021 Nimród László et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.